AlphaCentric Life Sciences & Hlthcare C holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.
AlphaCentric Life Sciences and Healthcare Fund Class C LYFCX
- NAV / 1-Day Return 18.66 / −0.43 %
- Total Assets 48.3M
-
Adj. Expense Ratio
2.410%
- Expense Ratio 2.400%
- Distribution Fee Level High
- Share Class Type Level Load
- Category Health
- Investment Style Mid Blend
- Min. Initial Investment 2,500
- Status Open
- TTM Yield 0.63%
- Turnover 164%
USD | NAV as of Jul 10, 2026 | 1-Day Return as of Jul 10, 2026, 12:58 AM GMT+0
Morningstar’s Analysis LYFCX
Will LYFCX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 41.8
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
First American Treasury Obligs X | 7.72 | 3M | Cash and Equivalents |
Gilead Sciences Inc | 7.18 | 3M | Healthcare |
AstraZeneca PLC | 5.63 | 2M | Healthcare |
Vertex Pharmaceuticals Inc | 5.60 | 2M | Healthcare |
Ionis Pharmaceuticals Inc | 3.74 | 1M | Healthcare |
Insmed Inc | 3.57 | 1M | Healthcare |
Incyte Corp | 3.41 | 1M | Healthcare |
Roivant Sciences Ltd Ordinary Shares | 3.36 | 1M | Healthcare |
argenx SE ADR | 3.33 | 1M | Healthcare |
Neurocrine Biosciences Inc | 3.22 | 1M | Healthcare |
United States